BJERKHOLT ERIC sold $978K of MIRM

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update – Q2 2026 net product sales of $176 million – 2026 net product sales guidance increased to $680 million to $700 million – Volixibat granted Breakthrough Therapy and Orpha

Mirum Pharmaceuticals reported Phase 2b results at the EASL Congress. In VISTAS, volixibat in primary sclerosing cholangitis reduced pruritus and the company plans an NDA submission in H2 2026. In AZURE-1, brelovitug in chronic hepatitis delta virus showed virologic response and ALT normalization at Week 24; Phase 3 topline data are expected later in 2026.

The article is largely promotional and does not provide verifiable details of Mirum Pharmaceuticals’ Phase 2b results for volixibat in PSC. It references an “EASL Congress” update but includes no specific efficacy/safety figures. It also promotes subscription offers and claims about prior stock-pick performance and “upside potential,” without citing sources.

Peetz Christopher (CHIEF EXECUTIVE OFFICER) sold 16,595 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $95.34 ($1.58M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Mirum Pharmaceuticals (Nasdaq: MIRM) presented late-breaking Phase 2b data at EASL 2026. In PSC, volixibat reduced cholestatic pruritus by 2.72 points (placebo-adjusted -1.64; p<0.0001) with 56% vs 26% achieving ≥2-point itch reduction. In HDV, brelovitug met a Week-24 endpoint in 45%/35% vs 0% (delayed). In PFIC, LIVMARLI improved event-free survival vs NAPPED (HR 0.29).

Simply Wall St discusses Mirum Pharmaceuticals (MIRM) and notes the company’s potential US$600 million zero-coupon convertible note issuance, saying it could affect the investment case. The piece frames “rewards” and “warning signs” based on historical data and analyst forecasts, and cautions it is general information, not financial advice.